Observational study of the efficacy of prolonged-release metformin in people with prediabetes.

Observational study of the efficacy of prolonged-release metformin in people with prediabetes. Curr Med Res Opin. 2019 Dec 03;:1 Authors: Hostalek U, Zilahi Z Abstract Objectives: Prediabetes is characterised by elevation of indices of blood glucose that is insufficient to provoke a diagnosis of type 2 diabetes, but markedly increases the risk of developing type 2 diabetes in the future. Lifestyle interventions are the main therapeutic intervention for the management of prediabetes. Current guidelines also support treatment of prediabetes with metformin for selected subgroups of patients, and metformin has a therapeutic indication for this use in a number of countries.Methods: We performed an observational, non-interventional study of the effects on glycaemia of prolonged-release metformin (Glucophage XR, referred to henceforth as metformin XR) in 686 subjects with prediabetes. Metformin was prescribed according to physicians' usual care practices, and the study duration was 12 weeks.Results: Mean (SD) fasting plasma glucose (FPG) at baseline was 6.2 (0.4) mmol/L [111 (8) mg/dL) and was reduced by -0.55 (0.7) mmol/L [-10 (13) mg/dL] after 12 weeks of metformin XR. FPG was normalised to below the American Diabetes Association cut-off for the diagnosis of prediabetes (
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research

Related Links:

Authors: Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Mendez-Sanchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M Abstract Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chr...
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
Non-Alcoholic Fatty Liver Disease (NAFLD), a progressive liver disease that is closely associated with obesity, type 2 diabetes, hypertension and dyslipidaemia, represents an increasing global public health challenge. There is significant variability in the disease course: the majority exhibit only fat accumulation in the liver but a significant minority develop a necroinflammatory form of the disease (non-alcoholic steatohepatitis, NASH) that may progress to cirrhosis and hepatocellular carcinoma.
Source: Contemporary Clinical Trials - Category: Radiology Authors: Source Type: research
Authors: Klujszo EH, Parcheta P, Witkowska AB, Krecisz B Abstract Non-alcoholic fatty liver disease (NAFLD) is the most common liver pathology in the western countries. Psoriatic patients are at higher risk of having NAFLD, and at higher risk of experiencing a more severe form of the disease with poorer outcomes. The components of the metabolic syndrome - obesity, lipid abnormalities, hypertension, and type 2 diabetes - significantly correlate with NAFLD progression. The inflammatory state present in psoriasis plays a significant role in development of NAFLD and the metabolic syndrome. All patients with psoriasis a...
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
Nonalcoholic fatty liver disease (NAFLD) has now become a relevant health care problem worldwide, as it affects approximately 25 –30% of adults in the general population, nearly 70% of patients with type 2 diabetes (T2DM) and almost all patients with obesity [1]. At present, the diagnosis of NAFLD is based on the following criteria: (a) hepatic steatosis on serum biomarker scores, imaging methods or histology, (b) no excess ive alcohol consumption (i.e.,
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Tags: Correspondence Source Type: research
AbstractAims/hypothesisThe aim of this study was to use Mendelian randomisation (MR) to identify the causal risk factors for type 2 diabetes.MethodsWe first conducted a review of meta-analyses and review articles to pinpoint possible risk factors for type 2 diabetes. Around 170 possible risk factors were identified of which 97 risk factors with available genetic instrumental variables were included in MR analyses. To reveal more risk factors that were not included in our MR analyses, we conducted a review of published MR studies of type 2 diabetes. For our MR analyses, we used summary-level data from the DIAbetes Genetics ...
Source: Diabetologia - Category: Endocrinology Source Type: research
Conclusions/interpretationLoneliness is a risk factor for type 2 diabetes. The mechanisms underlying this relationship remain to be elucidated.Graphical abstract
Source: Diabetologia - Category: Endocrinology Source Type: research
Conclusions/interpretationWhen included in the standard treatment for type 2 diabetes, dulaglutide significantly reduces LFC and improves GGT levels in participants with NAFLD. There were non-significant reductions in PFC, liver stiffness, serum AST and serum ALT levels. Dulaglutide could be considered for the early treatment of NAFLD in patients with type 2 diabetes.Trial registrationClinicalTrials.gov NCT03590626FundingThe current study was supported by an investigator-initiated study grant from Medanta –The Medicity’s departmental research fund and a grant from the Endocrine and Diabetes Foundation (EDF), In...
Source: Diabetologia - Category: Endocrinology Source Type: research
Conclusion: Our study provides evidence for insulin and lipid regulation of endocrine FGFs in healthy and PCOS women, suggesting that FGF family members play a role in lipid and glucose metabolism.Clinical Trial Registration:www.isrctn.org, Identifier: ISRCTN42448814.
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
ConclusionsCollectively, these data suggest that PPAR γ agonists, and specifically pioglitazone, could be potential therapeutics for the treatment of binge alcohol drinking.
Source: Psychopharmacology - Category: Psychiatry Source Type: research
“Lifestyle medicine is only for rich people, right?” a colleague asked me several years ago, questioning my involvement in this relatively new field of medicine that guides people toward healthy habits. This has been a common misperception, for sure. But across the US, a revitalized brand of health activism is intent on bringing lifestyle medicine to a broader range of people. This is backed by a new effort from the American College of Lifestyle Medicine to engage communities most affected by chronic disease. The first pillar of healthy lifestyle: Food is medicine Lifestyle medicine is an evidence-based practic...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Food as medicine Health Health care disparities Healthy Eating Source Type: blogs
More News: Alcoholism | Diabetes | Diabetes Type 2 | Diets | Endocrinology | Fortamet | Gastroenterology | Metformin | Nutrition | Research | Study | Weight Loss